Differences of the immune phenotype of breast cancer cells after ex vivo hyperthermia by warm-water or microwave radiation in a closed-loop system alone or in combination with radiotherapy

dc.bibliographicCitation.firstPage1082eng
dc.bibliographicCitation.issue5eng
dc.bibliographicCitation.journalTitleCancerseng
dc.bibliographicCitation.volume12eng
dc.contributor.authorHader, Michael
dc.contributor.authorSavcigil, Deniz Pinar
dc.contributor.authorRosin, Andreas
dc.contributor.authorPonfick, Philipp
dc.contributor.authorGekle, Stephan
dc.contributor.authorWadepohl, Martin
dc.contributor.authorBekeschus, Sander
dc.contributor.authorFietkau, Rainer
dc.contributor.authorFrey, Benjamin
dc.contributor.authorSchlücker, Eberhard
dc.contributor.authorGaipl, Udo S.
dc.date.accessioned2021-10-18T12:20:18Z
dc.date.available2021-10-18T12:20:18Z
dc.date.issued2020
dc.description.abstractThe treatment of breast cancer by radiotherapy can be complemented by hyperthermia. Little is known about how the immune phenotype of tumor cells is changed thereby, also in terms of a dependence on the heating method. We developed a sterile closed-loop system, using either a warm-water bath or a microwave at 2.45 GHz to examine the impact of ex vivo hyperthermia on cell death, the release of HSP70, and the expression of immune checkpoint molecules (ICMs) on MCF-7 and MDA-MB-231 breast cancer cells by multicolor flow cytometry and ELISA. Heating was performed between 39 and 44◦C. Numerical process simulations identified temperature distributions. Additionally, irradiation with 2 × 5 Gy or 5 × 2 Gy was applied. We observed a release of HSP70 after hyperthermia at all examined temperatures and independently of the heating method, but microwave heating was more effective in cell killing, and microwave heating with and without radiotherapy increased subsequent HSP70 concentrations. Adding hyperthermia to radiotherapy, dynamically or individually, affected the expression of the ICM PD-L1, PD-L2, HVEM, ICOS-L, CD137-L, OX40-L, CD27-L, and EGFR on breast cancer cells. Well-characterized pre-clinical heating systems are mandatory to screen the immune phenotype of tumor cells in clinically relevant settings to define immune matrices for therapy adaption. © 2020 by the authors. Licensee MDPI, Basel, Switzerland.eng
dc.description.versionpublishedVersioneng
dc.identifier.urihttps://oa.tib.eu/renate/handle/123456789/7007
dc.identifier.urihttps://doi.org/10.34657/6054
dc.language.isoengeng
dc.publisherBasel : MDPI AGeng
dc.relation.doihttps://doi.org/10.3390/cancers12051082
dc.relation.essn2072-6694
dc.rights.licenseCC BY 4.0 Unportedeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/eng
dc.subject.ddc610eng
dc.subject.otherBreast cancereng
dc.subject.otherDanger signalseng
dc.subject.otherEGFReng
dc.subject.otherHyperthermiaeng
dc.subject.otherImmune checkpoint moleculeseng
dc.subject.otherImmunogenic cancer cell phenotypeeng
dc.subject.otherImmunotherapyeng
dc.subject.otherMicrowave-heatingeng
dc.subject.otherMultimodal tumor therapieseng
dc.titleDifferences of the immune phenotype of breast cancer cells after ex vivo hyperthermia by warm-water or microwave radiation in a closed-loop system alone or in combination with radiotherapyeng
dc.typeArticleeng
dc.typeTexteng
tib.accessRightsopenAccesseng
wgl.contributorINPeng
wgl.subjectMedizin, Gesundheiteng
wgl.typeZeitschriftenartikeleng
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
cancers-12-01082.pdf
Size:
12.39 MB
Format:
Adobe Portable Document Format
Description:
Collections